Intramuscular ketamine vs. escitalopram and aripiprazole in acute and maintenance treatment of patients with treatment-resistant depression: a randomized double-blind clinical trial

HIGHLIGHTS

• who: Marco Aureu0301lio Cigognini from the University of Exeter, United Kingdom have published the research work: Intramuscular ketamine vs. escitalopram and aripiprazole in acute and maintenance treatment of patients with treatment-resistant depression: A randomized double-blind clinical trial, in the Journal: (JOURNAL)
• what: The aim of this test is to assess alternate attention. The aims of the planned study, besides the primary outcome of improving symptoms (as measured by the MADRS), is to assess the safety (VS) and tolerability of ketamine at sub-anesthetic doses and side effects, such as the development of depressive . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.